Business Wire

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023


Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that positive findings from the phase II clinical trial of ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, in patients with plaque psoriasis conducted in the United States and Canada (NCT05268016) were presented on 12 October at the European Association of Dermatology and Venereology (EADV) Congress 2023 held in Berlin.

The outline of the presentation is as follows:

Meiji Seika Pharma evaluated the efficacy and safety of ME3183, a novel oral, highly potent, selective phosphodiesterase-4 inhibitor, characterized by low blood-brain barrier transmission, over 16-week treatment period in adults with moderate to severe plaque psoriasis.

In total, 132 patients were randomly assigned to ME3183 (n=26, 26, 26, and 27, respectively) or placebo (n=27). Mean Psoriasis Area and Severity Index (PASI) score at baseline was 15.9–17.6 and 16.8 in the ME3183 and placebo groups, respectively. A significantly greater proportion of patients in the ME3183 5 mg BID, 7.5 mg BID, and 15 mg QD groups achieved ≥75% reduction from baseline PASI score (PASI-75) at Week 16 (primary endpoint) versus placebo (58.3%, 61.5%, and 52.0% vs 14.8%, P<0.001; 10 mg QD group: 32.0%). A greater proportion of patients in the ME3183 groups versus placebo achieved PASI-90, PASI-100, and Static Physician’s Global Assessment 0/1 combined with 2-point reduction (secondary endpoints). Early PASI improvement after administration was observed in the ME3183 groups. The most frequent treatment-emergent adverse events were diarrhea, nausea, and headache. In the ME3183 5 mg BID, 10 mg QD, 7.5 mg BID, 15 mg QD and placebo groups, 2, 2, 4, 3, and 1 patients, respectively, discontinued because of adverse events. ME3183 was well tolerated. No unexpected safety signals were observed.

In conclusion, ME3183 administered orally was effective in the treatment of plaque psoriasis and had an acceptable safety profile.

Meiji strives to provide efficacious and safe treatment for unmet medical needs, such as psoriasis and other autoimmune diseases.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Meiji Pharma USA Inc.
Yasushi Miyazawa
Telephone: +1-201-777-7133

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Sustainable Forestry Coalition Welcomes New Member, Suzano6.12.2023 11:37:00 CET | Press release

In September a group of leading global sustainable forestry companies launched the International Sustainable Forestry Coalition (ISFC), to enable the sector to positively contribute to global policy processes focused on the transition from a fossil-based economy to a circular bioeconomy. Today the ISFC is delighted to announce that Suzano, one of the world’s major forestry sector companies, has become a member. Suzano, headquartered in Brazil, is a globally respected forestry sector leader. With almost a hundred years in operation, the company manages extensive sustainable timber plantation estates and forest conservation areas, and creates a vast range of fibre-based products. One out of every three tissue products used in the world today will have come from Suzano’s operations. Convening Chair of the ISFC Dr. David Brand said, “With the inclusion of Suzano in the ISFC, the group represents more than 12.6 million hectares (31 million acres) of forests for conservation and production i

Forrester: European Retail Sales To Reach €2.7 Trillion By 20286.12.2023 11:00:00 CET | Press release

Forrester (Nasdaq: FORR) forecasts that total retail sales of Europe-5 countries (France, Germany, Italy, Spain, and the UK) will increase from €2.3 trillion in 2023 to reach €2.7 trillion in 2028 at a 2.9% compound annual growth rate (CAGR). Forrester’s recently released report, Europe-5 Online Retail Forecast, 2023 To 2028, estimates total retail sales, online retail sales, and online retail penetration across 22 product categories, including fashion, homeware, food and drink, consumer electronics, and media, for each of the Europe-5 economies. Germany holds the largest share of the retail market among these five countries, followed (in order) by the UK and France. In 2022, offline retail growth outpaced online retail growth for the first time as more consumers shopped in stores, and this momentum continued into 2023, but the fundamental growth drivers of online retail such as greater product selection, round-the-clock availability, and competitive pricing remain strong. As a result,

Kaneka Acquires Japan Medical Device Technology6.12.2023 10:40:00 CET | Press release

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary. This press release features multimedia. View the full release here: Stent before expansion (Photo: Business Wire) Kaneka manufactures and sells endovascular catheters, which are devices used in the treatment of cardiac, peripheral vascular, and cerebrovascular diseases. In particular, stenting*1 for the treatment of coronary artery diseases such as atherosclerosis has a market worth 30 billion yen in Japan, and Kaneka is aiming to expand its business in this area. JMDT has high technological capabilities in the research and development of coronary stents and is one of the lead

CommBox launches Era AI to enable customer service to be intelligently automated and CX costs to be cut by 40%6.12.2023 10:00:00 CET | Press release

Today CommBox, the pioneer in AI-powered customer communications, is launching its new generative AI solution. Designed for medium to large businesses across a range of industries including healthcare, banking, retail, telecommunications and insurance, Era AI is based on a winning combination of both proprietary technology developed by CommBox and commercial large language models. Era AI’s functionality scans enterprise knowledge sources and, in just seconds, provides customers with accurate, highly personalised information through the digital messaging channel of their choice. Era AI delivers customer service automation, reduces costs for organisations, and dramatically increases the speed and accuracy of enquiry handling. It does this all while increasing customer satisfaction, with CommBox customers seeing a 92% customer satisfaction rate on average. Central to this is Era AI’s ability to analyse a brand’s entire resource base, such as support articles, help and knowledge centres, a

New Post Hoc Phase 3 Data Analysis Shows AJOVY ® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity6.12.2023 08:00:00 CET | Press release

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announces that a post hoc analysis4 of two phase 3 clinical studies presented today at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY®(fremanezumab) in reducing migraine attacks in patients with migraine and co-morbid obesity. Migraine and obesity are both associated with high levels of disability3 and both conditions are more prevalent amongst females5,6. It is estimated that 59% of people in Europe are either overweight or obese, with almost a quarter (23%) of adults living with obesity5. A higher body mass index (BMI) is frequently associated with increased migraine prevalence and severity, and an increased number of adverse effects3. As such, assessing the efficacy and safety of migraine preventative treatment in patients with obesity can help guide migraine management and treatment decisions. The post hoc analysis of the HALO-LTS1 and FOCUS2 phase 3 studies compared the